激素受体阳性早期乳腺癌绝经前患者的辅助内分泌治疗选择：前瞻性 GIM23-POSTER 研究的见解。
Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study.
发表日期：2024 Jul 09
作者：
Luca Arecco, Maria Maddalena Latocca, Eva Blondeaux, Ferdinando Riccardi, Carmela Mocerino, Valentina Guarneri, Eleonora Mioranza, Giancarlo Bisagni, Elisa Gasparini, Fabio Puglisi, Alexandro Membrino, Antonella Ferro, Vincenzo Adamo, Filippo Giovanardi, Stefano Tamberi, Sara Donati, Elisabetta Landucci, Laura Biganzoli, Sara Piccinini, Simona Pastorino, Evandro de Azambuja, Francesca Poggio, Matteo Lambertini, Lucia Del Mastro
来源：
BREAST
摘要：
大多数绝经前早期乳腺癌 (eBC) 患者被诊断为激素受体阳性疾病，因此适合接受辅助内分泌治疗 (ET)。Gruppo Italiano Mammella (GIM) 23-POSTER (GIM23) 是一项多中心、前瞻性、观察性研究这项研究在 26 家意大利机构中进行，旨在评估现实环境中受激素受体阳性 eBC 影响的绝经前患者的 ET 选择。在此，我们还报告了根据 MonarchE 和 NATALEE 试验对高危患者的定义所开出的 ET 类型的结果。2019 年 10 月至 2022 年 6 月期间，纳入了 600 名绝经前患者，中位年龄为 46 岁。几乎一半 (271, 45.2%) 的患者患有 I 期疾病，而分别有 254 (42.3%) 和 60 (10.0%) 患者患有 II 期和 III 期疾病。总体而言，149 名 (25.1%) 名患者单独接受他莫昔芬治疗，83 名 (14.0%) 名患者接受他莫昔芬联合卵巢功能抑制 (OFS) 治疗，而 361 名 (60.9%) 名患者接受芳香酶抑制剂 (AI) 联合 OFS 治疗。接受 AI 和 OFS 治疗的患者的腋窝转移淋巴结数量较多、级别较高且接受化疗的频率较高（所有 p < 0.001）。根据君主E和NATALEE试验的纳入标准，81名患者（15.6%）被认为是君主E的高风险，并在88.9%的病例中接受了AI联合OFS，而231名患者（44.4%）被认为是高风险NATALEE 试验中，74.5% 的病例接受了 AI 联合 OFS 治疗。AI 联合 OFS 是绝经前患者中最常用的辅助 ET，尤其是在存在高风险特征的情况下。版权所有 © 2024 作者。由爱思唯尔有限公司出版。保留所有权利。
Most premenopausal patients with early breast cancer (eBC) are diagnosed with hormone receptor-positive disease and therefore candidate for adjuvant endocrine therapy (ET).The Gruppo Italiano Mammella (GIM) 23-POSTER (GIM23) is a multicenter, prospective, observational study conducted in 26 Italian institutions, aiming to evaluate ET choices for premenopausal patients affected by hormone receptor-positive eBC in a real-world setting. Here we report also the results in terms of type of ET prescribed according to the definition of high-risk patients by monarchE and NATALEE trials.Between October 2019 and June 2022, 600 premenopausal patients were included, with a median age of 46 years. Almost half (271, 45.2 %) of the patients had stage I disease, while 254 (42.3 %) and 60 (10.0 %) patients had stage II and III, respectively. Overall, 149 (25.1 %) patients received tamoxifen alone, 83 (14.0 %) tamoxifen with ovarian function suppression (OFS), while 361 (60.9 %) received aromatase inhibitor (AI) with OFS. Patients treated with AI and OFS had higher number of metastatic axillary nodes, higher grade and more often received chemotherapy (all p < 0.001). According to the inclusion criteria of the monarchE and NATALEE trials, 81 patients (15.6 %) were considered high-risk for the monarchE and received AI with OFS in 88.9 % of the cases, while 231 patients (44.4 %) were considered high-risk for the NATALEE trial and received AI with OFS in 74.5 % of cases.AI with OFS is the most prescribed adjuvant ET among premenopausal patients, especially in the presence of high-risk features.Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.